Summary of Conference Call Records Industry Overview - The life sciences service sector, particularly the CXO segment, continues to experience high growth and is expected to deliver strong performance in 2026, benefiting from the upward cycle in innovative drugs and improved investment conditions [1][2][3] Key Companies and Performance - Notable companies in the life sciences service industry include: - **Hao Yuan Medicine**: Q3 revenue growth close to 30%, with a non-recurring profit growth of 70%. The company has secured orders exceeding 630 million yuan, a 50% year-on-year increase [2][8] - **Bai Ao Sai Tu**: Achieved a revenue growth of 60% in Q3 and recorded its first annual profit, with significant potential in humanized mouse sales and antibody business [2][8] - **WuXi AppTec**: Expected to see over 60% revenue growth in the ADC sector in the first half of 2026, with a strong order backlog [10][19] - **Kailai Ying**: Positioned well in the ADC market, with significant growth potential [10][19] - **Yangguang Nuohe**: Anticipated to achieve a profit of 300 million yuan in 2026, with a promising drug pipeline [20] Financial Performance - In the first three quarters of 2025, 16 representative life sciences service companies reported revenue and profit growth rates of high single digits and double digits, respectively. In Q3 alone, revenue and profit growth rates were double digits and 50%, indicating significant operational improvement [4][6] - The gross profit margin is expected to improve due to a clearer competitive landscape, leading to enhanced industry profitability [4] Market Trends - The overseas market is benefiting from improved investment conditions and the Federal Reserve's interest rate cuts, leading to an increase in the share of overseas business and expanding global market potential [7] - The domestic CRO market is experiencing a price recovery trend after years of intense competition, with expectations for more significant price improvements by 2027 as supply conditions stabilize [11][12] Growth Opportunities - The ADC and small nucleic acid sectors are projected to bring substantial order increases in 2026, with companies like WuXi AppTec and Hao Yuan Medicine expected to lead this growth [10][19] - The CRO sector is seeing a shift towards innovation, with companies like Yangguang Nuohe and Chengdu Xian Dao making progress in developing innovative drugs [13] Investment Recommendations - Recommended companies for investment include: - **WuXi AppTec**: Strong growth in peptide business and expected to achieve significant revenue increases [14][17] - **Kailai Ying**: Leading in peptide capacity expansion [14] - **Tigermed**: Positioned well in the CRO market with growth potential [21] - **Norseg and Prasis**: Expected to benefit from overall industry trends [17] Conclusion - The life sciences service industry is poised for continued growth, driven by innovative drug development, improved investment conditions, and a recovering market landscape. Key players are expected to deliver strong financial performance, making them attractive investment opportunities.

优化，成就与众不同 Optimization Makes Differences 证券代码：688293 证券简称：奥浦迈 上海奥浦迈生物科技股份有限公司 2026 年第一次临时股东会 会议资料 二〇二六年一月 1 二、为保证本次会议的严肃性和正常秩序，切实维护股东的合法权益，请出 席会议的股东或其代理人或其他出席者至少提前 30 分钟到达会场签到确认参会 资格。在会议主持人宣布现场出席会议的股东和代理人人数及所持有表决权的股 份总数之前，会议登记应当终止。 三、会议按照会议通知上所列顺序审议、表决议案。 四、股东及股东代理人参加股东会依法享有发言权、质询权、表决权等权利。 股东及股东代理人参加股东会应认真履行其法定义务，不得侵犯公司和其他股东 及股东代理人的合法权益，不得扰乱股东会的正常秩序。 | 2026 年第一次临时股东会会议须知 3 | | --- | | 2026 年第一次临时股东会会议议程 6 | | 议案 1： 8 | | 《关于补选公司第二届董事会独立董事的议案》 8 | 优化，成就与众不同 Optimization Makes Differences 上海奥浦迈生物科技股份有限公司 2026 ...

工银前沿医疗股票A（001717）成立日期2016年2月3日，最新规模96.36亿。今年以来收益17.03%，同 类排名3002/4189；近一年收益17.03%，同类排名3002/4189；成立以来收益207.9%。 从奥浦迈十大流通股东角度 数据显示，工银瑞信基金旗下1只基金位居奥浦迈十大流通股东。工银前沿医疗股票A（001717）三季 度增持40万股，持有股数330.01万股，占流通股的比例为2.91%。根据测算，今日浮盈赚取约811.82万 元。 1月5日，奥浦迈涨5.02%，截至发稿，报51.46元/股，成交2702.97万元，换手率0.47%，总市值58.57亿 元。 资料显示，上海奥浦迈生物科技股份有限公司位于上海市浦东新区紫萍路908弄28号楼，成立日期2013 年11月27日，上市日期2022年9月2日，公司主营业务涉及从事细胞培养产品与服务。主营业务收入构成 为：产品87.34%，服务12.53%，其他0.13%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投 ...

Group 1 - The core viewpoint of the news is that Aopumai has shown significant growth in revenue and net profit, indicating a positive financial performance [2] - As of December 31, Aopumai's stock price increased by 1.55%, with a trading volume of 33.34 million yuan, and a net financing buy of -1.20 million yuan [1] - The financing balance of Aopumai is 94.02 million yuan, which is 1.69% of its market capitalization, indicating a low financing level compared to the past year [1] Group 2 - For the period from January to September 2025, Aopumai achieved an operating income of 272 million yuan, representing a year-on-year growth of 25.79% [2] - The net profit attributable to the parent company for the same period was 49.43 million yuan, showing an impressive year-on-year increase of 81.48% [2] - Aopumai has distributed a total of 173 million yuan in dividends since its A-share listing [3] Group 3 - As of September 30, 2025, Aopumai had 3,682 shareholders, an increase of 14.63% from the previous period, with an average of 30,838 circulating shares per shareholder, up by 27.96% [2] - Among the top ten circulating shareholders, several institutional investors have increased their holdings, indicating growing institutional interest in Aopumai [3]

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].

截至2025年12月26日收盘，奥浦迈（688293）报收于52.32元，较上周的52.66元下跌0.65%。本周，奥 浦迈12月22日盘中最高价报53.2元。12月25日盘中最低价报51.2元。奥浦迈当前最新总市值55.77亿元， 在生物制品板块市值排名40/51，在两市A股市值排名3086/5181。 本周关注点 公司公告汇总 公司拟向PharmaLegacy Hong Kong Limited等31名股东发行约14,500,000股股份用于购买资产，并在12个 月内分期发行不超过7,249,516股股份。同时，计划向不超过35名特定投资者发行股份募集配套资金不超 过362,049,857元，导致总股本将相应增加。 业绩披露要点机构调研要点 公司于2026年1月1日发布报告书修订说明，更新了本次交易已履行的决策程序及上市公司注册资本信 息，删除原有关于募集配套资金需经上交所审核和证监会注册的表述，因已取得证监会同意注册批复。 交易信息汇总 奥浦迈拟以发行股份及支付现金方式收购澎立生物医药技术（上海）股份有限公司100.00%股权，交易 价格为145,050.07万元，其中股份支付74,048.70万元，现 ...

证券代码：688293 证券简称：奥浦迈 上市地点：上海证券交易所 上海奥浦迈生物科技股份有限公司 发行股份及支付现金购买资产 并募集配套资金报告书（摘要） | 项目 | 交易对方 | | --- | --- | | | PharmaLegacy Hong Kong Limited、嘉兴汇拓企业管理合伙企业 | | | （有限合伙）、红杉恒辰（厦门）股权投资合伙企业（有限合 | | | 伙）、宁波梅山保税港区谷笙澎立投资合伙企业（有限合伙）、 | | | TF PL LTD.、上海高瓴辰钧股权投资合伙企业（有限合伙）、杭 | | | 州泰格股权投资合伙企业（有限合伙）、南通东证富象股权投资 | | | 中心（有限合伙）、江西济麟鑫盛企业管理有限公司、中金启辰 | | | 贰期（苏州）新兴产业股权投资基金合伙企业（有限合伙）、嘉 | | | 兴合拓企业管理合伙企业（有限合伙）、苏州晨岭投资合伙企业 | | | （有限合伙）、德州两仪幂方康健创业投资合伙企业（有限合 | | | 伙）、平阳国凯股权投资合伙企业（有限合伙）、苏州一元幂方 | | 发行股份及支付现金购买资产 | 医药创业投资合伙企业（有限合伙）、武汉 ...

国泰海通证券股份有限公司 关于 上海奥浦迈生物科技股份有限公司 发行股份及支付现金购买资产并募集配套 资金 之 独立财务顾问报告 独立财务顾问 签署日期：二〇二五年十二月 声明与承诺 本部分所使用的简称与本报告"释义"中所定义的简称具有相同含义。 国泰海通证券股份有限公司接受上海奥浦迈生物科技股份有限公司的委托， 担任上海奥浦迈生物科技股份有限公司发行股份及支付现金购买资产并募集配 套资金的独立财务顾问，就该事项向上海奥浦迈生物科技股份有限公司全体股东 提供独立意见，并制作本独立财务顾问报告。 本独立财务顾问报告是依据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务管 理办法》《公开发行证券的公司信息披露内容与格式准则第 26 号——上市公司 重大资产重组》《上海证券交易所上市公司自律监管指引第 6 号—重大资产重组》 等法律、法规的有关规定，按照证券行业公认的业务标准、道德规范和诚实信用、 勤勉尽责精神，遵循客观、公正的原则，在认真审阅相关资料和充分了解本次交 易行为的基础上，发表独立财务顾问意见，旨在就本次交易做出独立、客观和公 正的评价，以 ...

证券代码：688293 证券简称：奥浦迈 上市地点：上海证券交易所 上海奥浦迈生物科技股份有限公司 发行股份及支付现金购买资产 并募集配套资金报告书 | 项目 | 交易对方 | | --- | --- | | | PharmaLegacy Hong Kong Limited、嘉兴汇拓企业管理合伙企业 | | | （有限合伙）、红杉恒辰（厦门）股权投资合伙企业（有限合 | | | 伙）、宁波梅山保税港区谷笙澎立投资合伙企业（有限合伙）、 | | | TF PL LTD.、上海高瓴辰钧股权投资合伙企业（有限合伙）、杭 | | | 州泰格股权投资合伙企业（有限合伙）、南通东证富象股权投资 | | | 中心（有限合伙）、江西济麟鑫盛企业管理有限公司、中金启辰 | | | 贰期（苏州）新兴产业股权投资基金合伙企业（有限合伙）、嘉 | | | 兴合拓企业管理合伙企业（有限合伙）、苏州晨岭投资合伙企业 | | | （有限合伙）、德州两仪幂方康健创业投资合伙企业（有限合 | | | 伙）、平阳国凯股权投资合伙企业（有限合伙）、苏州一元幂方 | | 发行股份及支付现金购买资产 | 医药创业投资合伙企业（有限合伙）、武汉泰明创业 ...

2025 年 12 月 31 日，公司收到中国证券监督管理委员会出具的《关于同意 上海奥浦迈生物科技股份有限公司发行股份购买资产并募集配套资金注册的批 复》（证监许可〔2025〕3036 号）。 "一、同意你公司自本批复下发之日起 12 个月内向红杉恒辰（厦门）股权 投资合伙企业（有限合伙）发行 3,254,163 股股份、向上海景数创业投资中心（有 限合伙）发行 2,319,427 股股份、向中金启辰贰期（苏州）新兴产业股权投资基 金合伙企业（有限合伙）发行 1,463,620 股股份、向江西济麟鑫盛企业管理有限 公司发行 1,072,250 股股份、向德州两仪幂方康健创业投资合伙企业（有限合伙） 发行 938,399 股股份、向上海高瓴辰钧股权投资合伙企业（有限合伙）发行 770,523 股股份、向苏州晨岭投资合伙企业（有限合伙）发行 724,513 股股份、向上海陂 季玟企业管理合伙企业（有限合伙）发行 715,311 股股份、向苏州一元幂方医药 创业投资合伙企业（有限合伙）发行 707,032 股股份、向上海君澎投资中心（有 限合伙）发行 596,092 股股份、向南通东证富象股权投资中心（有限合伙） ...